Aliases & Classifications for Keloid Disorder

MalaCards integrated aliases for Keloid Disorder:

Name: Keloid Disorder 73
Keloid 54 17
Keloids 6

External Ids:

Summaries for Keloid Disorder

MalaCards based summary : Keloid Disorder, also known as keloid, is related to scleroderma, familial progressive and localized scleroderma. An important gene associated with Keloid Disorder is ASAH1 (N-Acylsphingosine Amidohydrolase 1), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and breast, and related phenotype is skeleton.

Wikipedia : 73 Keloid, also known as keloid disorder and keloidal scar, is the formation of a type of scar which,... more...

Related Diseases for Keloid Disorder

Diseases related to Keloid Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 326)
# Related Disease Score Top Affiliating Genes
1 scleroderma, familial progressive 29.9 CD36 BMP6
2 localized scleroderma 29.8 TGFB1 BMP6
3 fibrodysplasia ossificans progressiva 29.4 TGFB1 BMP6
4 hypertrophic scars 29.3 TGFB1 CD36 BMP6
5 gingival overgrowth 29.2 TGFB1 CD36
6 pulmonary fibrosis, idiopathic 28.8 TGFB1 SERPINH1 BMP6
7 torticollis, keloids, cryptorchidism, and renal dysplasia 11.5
8 premature aging syndrome, penttinen type 11.4
9 frontometaphyseal dysplasia 2 11.1
10 warburg-cinotti syndrome 11.1
11 x-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome 10.9
12 myhre syndrome 10.9
13 desmoid tumor 10.9
14 trueb burg bottani syndrome 10.9
15 acne 10.4
16 overgrowth syndrome 10.4
17 fibrosis of extraocular muscles, congenital, 1 10.3
18 systemic scleroderma 10.3
19 chromosome 2q35 duplication syndrome 10.2
20 folliculitis 10.2
21 dowling-degos disease 1 10.1
22 blastomycosis 10.1
23 telangiectasis 10.1
24 47,xyy 10.1
25 insulin-like growth factor i 10.1
26 dermatofibrosarcoma protuberans 10.1
27 helix syndrome 10.1
28 dermatitis 10.1
29 herpes zoster 10.1
30 hypoxia 10.1
31 dermatitis, atopic 10.0
32 rapidly involuting congenital hemangioma 10.0
33 leiomyoma 10.0
34 cholecystolithiasis 10.0 TGFB1 BMP6
35 eosinophilia-myalgia syndrome 10.0 TGFB1 BMP6
36 tuberculoid leprosy 10.0 TGFB1 BMP6
37 hemangioma 10.0
38 microvascular complications of diabetes 3 10.0 TGFB1 BMP6
39 breast cyst 10.0 TGFB1 BMP6
40 sarcoidosis 1 9.9
41 sarcoma 9.9
42 skin atrophy 9.9
43 tracheal stenosis 9.9
44 spindle cell sarcoma 9.9
45 severe combined immunodeficiency 9.9
46 cytokine deficiency 9.9
47 soft tissue sarcoma 9.9
48 pneumoconiosis 9.9 TGFB1 H19
49 bronchiolitis obliterans 9.9 TGFB1 BMP6
50 osteofibrous dysplasia 9.9 TGFB1 CD36

Graphical network of the top 20 diseases related to Keloid Disorder:



Diseases related to Keloid Disorder

Symptoms & Phenotypes for Keloid Disorder

MGI Mouse Phenotypes related to Keloid Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 skeleton MP:0005390 9.02 ASAH1 BMP6 CD36 SERPINH1 TGFB1

Drugs & Therapeutics for Keloid Disorder

Drugs for Keloid Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
4
Povidone-iodine Approved Phase 4 25655-41-8
5
Ethanol Approved Phase 4 64-17-5 702
6
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Tocopherol Approved, Investigational Phase 4 1406-66-2
9
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
10
Prilocaine Approved Phase 4 721-50-6 4906
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Fluorouracil Approved Phase 4 51-21-8 3385
13
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
14
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
15
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
16
Verapamil Approved Phase 4 52-53-9 2520
17
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
18 Tocotrienol Investigational Phase 4 6829-55-6
19 Trace Elements Phase 4
20 Nutrients Phase 4
21 Micronutrients Phase 4
22 Gastrointestinal Agents Phase 4
23 Antiemetics Phase 4
24 Protective Agents Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 Lidocaine, Prilocaine Drug Combination Phase 4
27 Antioxidants Phase 4
28 Hydrocortisone 17-butyrate 21-propionate Phase 4
29 Hydrocortisone hemisuccinate Phase 4
30 Vitamins Phase 4
31 Tocotrienols Phase 4
32 Tocopherols Phase 4
33 Chlorhexidine gluconate Phase 4
34 Pharmaceutical Solutions Phase 4
35 Antimetabolites Phase 4
36 Anesthetics Phase 4
37 Anesthetics, Local Phase 4
38 Sodium Channel Blockers Phase 4
39 abobotulinumtoxinA Phase 4
40 Diuretics, Potassium Sparing Phase 4
41 Cholinergic Agents Phase 4
42 Botulinum Toxins, Type A Phase 4
43 Neurotransmitter Agents Phase 4
44 Botulinum Toxins Phase 4
45 Anti-Bacterial Agents Phase 4
46 Antibiotics, Antitubercular Phase 4
47 Hormones Phase 4
48 Calcium, Dietary Phase 4
49 Immunosuppressive Agents Phase 4
50 Triamcinolone hexacetonide Phase 4

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease Unknown status NCT01295099 Phase 4 5- fluorouracil;Triamcinolone
2 Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery Unknown status NCT02521402 Phase 4
3 Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars Completed NCT01078428 Phase 4
4 Combined Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence.A Randomized Controlled Trial. Completed NCT03239964 Phase 4 Dexamethasone
5 A Prospective, Randomized, Investigator-blinded, Placebo-controlled, Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars Completed NCT00754247 Phase 4 0.5% hydrocortisone, silicone, vitamin E lotion;Onion extract gel;Cetearyl alcohol lotion
6 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
7 Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars Completed NCT01789346 Phase 4
8 The Efficacy of Laser Assisted Hair Removal in the Treatment of Acne Keloidalis Nuchae; a Pilot Study Completed NCT01548898 Phase 4
9 A Double Blind Randomized Controlled Trial Comparing the Efficacy of 7% Lidocaine / 7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream for Local Anaesthesia During Laser Treatment of Acne Keloidalis Nuchae and Tattoo Removal Completed NCT02372786 Phase 4 2,5% lidocaine / 2,5% prilocaine cream;7% lidocaine / 7% tetracaine cream
10 Intralesional Injection of Steroids and/or Botulinum Toxin Type A in Hypertrophic Scars and Keloids for Pain Improvement Recruiting NCT03982862 Phase 4 Triamcinolone;Lidocaine;Botulinum toxin A
11 A Prospective Triple-Blinded Single-Center Study of Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid Treatment for Keloids Recruiting NCT04786210 Phase 4
12 Intralesional Bleomycin Treatment of Keloids Using an Electronic Pneumatic Jet Injector: a Double-blind Randomized, Placebo-controlled Trial With Split-lesion Design Not yet recruiting NCT04582305 Phase 4 Bleomycin;Normal saline
13 Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal Terminated NCT01720056 Phase 4 Verapamil;Kenalog 10
14 Effect of Infra-red Diode Laser on Improvement of Surgical Scar and on the Prevention of Excised Keloids Recurrence-Pilot Study Unknown status NCT01158196 Phase 3
15 Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children Unknown status NCT01113125 Phase 3 Betamethason-17-valerate and fusidic acid;Fusidic Acid
16 Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars: 3-arm Trial Unknown status NCT02823236 Phase 3 Topical Pirfenidone;Triamcinolone + Pirfenidone;Intralesional Triamcinolone
17 Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Hypertrophic Scars and Keloids Scars. Completed NCT00993005 Phase 3
18 Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars: a Randomized Controlled Trial Completed NCT01861119 Phase 3 Silicone gel Kelo-cort™;;Onion extract gel Contractubex™
19 The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study Completed NCT00129428 Phase 1, Phase 2
20 A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloids Completed NCT00892723 Phase 2 AZX100 Drug Product;Placebo;AZX100 Drug Product
21 A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product Following Excision of Keloids Completed NCT00825916 Phase 2 AZX100 Drug Product;AZX100 Drug Product;Placebo
22 A Single-centre, Double Blind, Randomised, Exploratory Study to Explore the Efficacy and Safety of Juvista 250ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids. Completed NCT00836147 Phase 1, Phase 2 Avotermin (Juvista);Placebo
23 A Single-centre, Double Blind, Randomised, Tolerance Study to Investigate the Safety of Juvista 500ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids. Completed NCT00710333 Phase 1, Phase 2 Avotermin;placebo
24 A Prospective, Randomized, Comparative Feasibility Study Evaluating the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Adjunctive to Surgical Scar Revision Completed NCT01446770 Phase 2
25 A Phase 2, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of MRG-201 Following Intradermal Injection in Subjects With a History of Keloids Completed NCT03601052 Phase 2 Remlarsen;Placebo
26 A Prospective, Randomized, Controlled Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids Completed NCT00587587 Phase 1, Phase 2
27 A Single-centre, Double Blind, Randomised, Rising Dose Tolerance Study to Investigate the Safety of Juvista When Administered Following Excision of Ear Lobe Keloids. Completed NCT00469235 Phase 1, Phase 2 Avotermin
28 A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults Completed NCT02079168 Phase 2 RXI-109;Placebo
29 Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study Not yet recruiting NCT04326959 Phase 1, Phase 2
30 Efficacy of Autologous Adipose Derived Stromal Vascular Fraction in the Treatment of Keloids Not yet recruiting NCT04391621 Phase 2 Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
31 Autologous Adipose Derived Stem Cell Transplantation in the Treatment of Keloids. A Pilot Randomized Controlled Trial Not yet recruiting NCT04553159 Phase 2
32 A Therapeutic Trial of Intralesional Bevacizumab in Patients With Non-pedunculated Keloids Terminated NCT01408953 Phase 2
33 Open-label, Single-arm Pilot Study of the Effects of Topical 5% Imiquimod Cream on Preventing Keloid Recurrence After Surgical Keloidectomy Terminated NCT03760250 Phase 2 Imiquimod 5% cream
34 A Post-shave Keloid Recurrence Study in Two Parts: A Biomarker Assessment Followed by a Randomized, Double-blind, Placebo Controlled Evaluation of Safety, Tolerability, and Efficacy of QAX576 Terminated NCT00987545 Phase 2 QAX576;QAX576 placebo
35 Phase II Trial of Sorafenib in Patients With Extensive Keloids Terminated NCT01425216 Phase 2 Sorafenib
36 Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars Withdrawn NCT02546076 Phase 2
37 Calcium Electroporation for the Treatment of Keloids Completed NCT01941914 Phase 1 Calcium chloride
38 Phase I Study of High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin Completed NCT02630303 Phase 1
39 An Exploratory Study to Evaluate the Safety and Efficacy of Intradermal Administration of AIV001 Aqueous Suspension on Scar Formation and Keloid Recurrence Following Keloidectomy Not yet recruiting NCT04827875 Phase 1 AIV001
40 A Randomised Open Label Placebo Controlled Study to Evaluate Fractional Collagen Synthesis in Keloids and Identify Biomarkers of Keloid Biology for Potential Application in Future Clinical Trials Terminated NCT01978301 Phase 1 Triamcinolone acetonide;Placebo
41 Comparison of the Effectiveness in Prevention of Hypertrophic Scars or Keloids Between Silicone Sheet, Silicone Gel and Paper Steri-strip-A Randomised Controlled Trial. Unknown status NCT00849004
42 Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage for Standardised Total Ear Reconstruction Unknown status NCT00565552 Silicone gel (Dermatix®)
43 A Retrospective Registry Study to Evaluate the Long-Term Efficacy and Safety of Superficial Radiation Therapy (SRT) for the Treatment of Recurrent Keloid Scars. Unknown status NCT03693924
44 Intralesional Cryosurgery for the Treatment of Basal Cell Carcinoma of the Lower Extremities in the Elderly - a Feasibility Study Unknown status NCT01633515
45 First Study Evaluating Efficiency and Safety of a Compressive Device to Prevent Keloid Scars Recurrence After Surgery Unknown status NCT03312166
46 Microcyn Scar Management HydroGel, K103163 vs. Kelo-cote® Scar Gel for the Management of Hypertrophic or Keloid Scars Unknown status NCT01736969
47 Comparison of the Blister Fluid Components of Second Degree Burned Patients With the Blister Fluid Components Following Intralesional Cryosurgery of Keloid Scars - A Feasibility Study. Unknown status NCT01627769
48 Prospective, Controlled Study of the Efficacy of NdYag for Acne Keloidalis Nuchae Unknown status NCT00757315 Topical corticosteroid alone
49 The Effectiveness Of UVA1 Irradiation In The Treatment Of Skin Conditions With Altered Dermal Matrix: A Controlled, Cross-Over Study Completed NCT00476801
50 A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid LEsions Treated Adjunctive to suRgical Excision. PMCS: EURO-KLEAR Completed NCT01706861

Search NIH Clinical Center for Keloid Disorder

Genetic Tests for Keloid Disorder

Anatomical Context for Keloid Disorder

MalaCards organs/tissues related to Keloid Disorder:

40
Skin, Endothelial, Breast, Eye, Tongue, Bone, Smooth Muscle

Publications for Keloid Disorder

Articles related to Keloid Disorder:

(show top 50) (show all 3273)
# Title Authors PMID Year
1
Identification of ASAH1 as a susceptibility gene for familial keloids. 61 6
28905881 2017
2
Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars. 54 61
20428796 2010
3
Syndecan-2 and decorin: proteoglycans with a difference--implications in keloid pathogenesis. 54 61
20386290 2010
4
Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. 54 61
19772524 2010
5
Topical tamoxifen therapy in hypertrophic scars or keloids in burns. 54 61
19636578 2010
6
Keloid scarring: new treatments ahead. 54 61
20096165 2009
7
Elastic fiber assembly is disrupted by excessive accumulation of chondroitin sulfate in the human dermal fibrotic disease, keloid. 54 61
19879246 2009
8
Human embryonic stem cell-derived mesoderm-like epithelium transitions to mesenchymal progenitor cells. 61 54
19196144 2009
9
Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid. 61 54
19546682 2009
10
Low decorin expression along with inherent activation of ERK1,2 in ear lobe keloids. 61 54
19268470 2009
11
[Expression of Smads in keloid scarring]. 61 54
19781253 2009
12
Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. 61 54
19289101 2009
13
[The effect of tunicamycin on Fas protein expression and its function in fibroblasts from hypertrophic scar and keloid]. 54 61
19803206 2009
14
Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression. 54 61
19438747 2009
15
Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. 54 61
19120328 2009
16
Keloid scarring: bench and bedside. 54 61
19360429 2009
17
Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. 61 54
19037237 2009
18
[Expression and function of sphingosine kinases 1 and 2 in human keloid fibroblasts]. 54 61
19567073 2009
19
Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts. 61 54
18787533 2009
20
Basic fibroblast growth factor: a potential new therapeutic tool for the treatment of hypertrophic and keloid scars. 54 61
19071002 2009
21
[Comparison of the mechanisms of intralesional steroid, interferon or verapamil injection in the treatment of proliferative scars]. 54 61
19408724 2009
22
Keloidal basal cell carcinoma: not a distinctive clinicopathological entity. 61 54
18795924 2009
23
Keloid banding using suture ligature: a novel technique and review of literature. 61 54
18978483 2008
24
Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts. 61 54
18832570 2008
25
Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. 61 54
18463684 2008
26
The use of corticosteroids to treat keloids: a review. 61 54
18611924 2008
27
DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. 61 54
18406579 2008
28
[The expression of fibrillin 1 in pathologic scars and its significance]. 61 54
19119630 2008
29
TGF-beta1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts. 61 54
18575776 2008
30
Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. 61 54
17943180 2008
31
Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture. 61 54
18087663 2008
32
[The role of cell pathway in apoptosis of fibroblasts from proliferative scar induced by steroid or IFN]. 61 54
18437985 2008
33
Targeting of Sp1 transcription factor: a novel therapeutic approach for keloids, an in vitro analysis. 61 54
18031462 2007
34
Increased CCN2 transcription in keloid fibroblasts requires cooperativity between AP-1 and SMAD binding sites. 54 61
17968183 2007
35
Transforming growth factor beta (TGFbeta) and keloid disease. 61 54
17660136 2007
36
Effect of heat shock protein 47 on collagen accumulation in keloid fibroblast cells. 54 61
17535221 2007
37
Fas-mediated apoptotic signal transduction in keloid and hypertrophic scar. 61 54
17440345 2007
38
[The expression of periostin in hyperplasic scars and the relations to TGF-beta1 and its receptors]. 54 61
17649947 2007
39
Flashlamp pulsed-dye laser suppressed TGF-beta1 expression and proliferation in cultured keloid fibroblasts is mediated by MAPK pathway. 54 61
17457842 2007
40
Exogenous nitric oxide stimulated collagen type I expression and TGF-beta1 production in keloid fibroblasts by a cGMP-dependent manner. 54 61
17052928 2007
41
[Discoidin domain receptors (DDRs) expression in pathological scar fibroblast formation]. 61 54
17554880 2007
42
Induction of TIMP-1 and HSP47 synthesis in primary keloid fibroblasts by exogenous nitric oxide. 54 61
17145168 2007
43
Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. 61 54
17889631 2007
44
Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signaling pathways. 54 61
16841034 2006
45
Modulation of collagen synthesis in keloid fibroblasts by silencing Smad2 with siRNA. 54 61
17051103 2006
46
[Expressions of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids]. 61 54
17144456 2006
47
Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. 54 61
16705627 2006
48
Upregulation of TGF-beta1 expression may be necessary but is not sufficient for excessive scarring. 61 54
16498396 2006
49
Elevated prolidase activity in keloids: correlation with type I collagen turnover. 54 61
16634881 2006
50
P38 MAP kinase mediates transforming growth factor-beta2 transcription in human keloid fibroblasts. 61 54
16467496 2006

Variations for Keloid Disorder

ClinVar genetic disease variations for Keloid Disorder:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ASAH1 NM_177924.5(ASAH1):c.1154T>C (p.Leu385Pro) SNV Pathogenic/Likely pathogenic 417797 rs368345612 GRCh37: 8:17915077-17915077
GRCh38: 8:18057568-18057568
2 AGPAT5 NM_018361.4(AGPAT5):c.926G>A (p.Gly309Glu) SNV Benign 430635 rs368348075 GRCh37: 8:6614740-6614740
GRCh38: 8:6757219-6757219

Expression for Keloid Disorder

Search GEO for disease gene expression data for Keloid Disorder.

Pathways for Keloid Disorder

Pathways related to Keloid Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.43 TGFB1 CD36
2 11.3 TGFB1 BMP6
3 11.23 TGFB1 BMP6
4 10.98 TGFB1 CD36
5 10.65 TGFB1 CD36
6 10.61 TGFB1 SERPINH1 BMP6

GO Terms for Keloid Disorder

Cellular components related to Keloid Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 TGFB1 SERPINH1 CD36 BMP6 ASAH1
2 collagen trimer GO:0005581 8.96 SERPINH1 CD36

Biological processes related to Keloid Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.65 TGFB1 CD36 BMP6
2 BMP signaling pathway GO:0030509 9.51 TGFB1 BMP6
3 cellular response to mechanical stimulus GO:0071260 9.49 TGFB1 BMP6
4 SMAD protein signal transduction GO:0060395 9.46 TGFB1 BMP6
5 positive regulation of epithelial cell proliferation GO:0050679 9.43 TGFB1 BMP6
6 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.4 TGFB1 BMP6
7 positive regulation of protein secretion GO:0050714 9.37 TGFB1 BMP6
8 positive regulation of bone mineralization GO:0030501 9.32 TGFB1 BMP6
9 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.26 H19 CD36
10 positive regulation of SMAD protein signal transduction GO:0060391 9.16 TGFB1 BMP6
11 positive regulation of vascular permeability GO:0043117 8.96 TGFB1 BMP6
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 8.8 TGFB1 CD36 BMP6

Sources for Keloid Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....